Thiazolidinediones in patients with type 2 diabetes mellitus and heart failure
- 1 May 2007
- journal article
- review article
- Published by Oxford University Press (OUP) in American Journal of Health-System Pharmacy
- Vol. 64 (9), 931-936
- https://doi.org/10.2146/ajhp060446
Abstract
Purpose. A review of the significant findings related to the use of the thiazolidinediones (TZDs) in the treatment of patients with type 2 diabetes mellitus and heart failure was conducted.Keywords
This publication has 30 references indexed in Scilit:
- Dose-response relation between sulfonylurea drugs and mortality in type 2 diabetes mellitus: a population-based cohort studyCMAJ : Canadian Medical Association Journal, 2006
- Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trialThe Lancet, 2005
- Pioglitazone initiation and subsequent hospitalization for congestive heart failureDiabetic Medicine, 2005
- Insulin-treated diabetes is associated with a marked increase in mortality in patients with advanced heart failureAmerican Heart Journal, 2005
- Approach to the management of diabetic patients with heart failure: Role of thiazolidinedionesAmerican Heart Journal, 2004
- Peroxisome Proliferator Activator Receptors (PPAR), Insulin Resistance, and CardiomyopathyCardiology in Review, 2004
- Use of glitazones in cardiac patients: a case for B-type natriuretic peptide monitoring?The American Journal of Cardiology, 2004
- Glitazones and Heart FailureCirculation, 2003
- Metabolic and Additional Vascular Effects of ThiazolidinedionesDrugs, 2002
- Role of diabetes in congestive heart failure: The Framingham studyThe American Journal of Cardiology, 1974